| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.9 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.9 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | 0.018 | 0.9 |